证券代码：688553 证券简称：汇宇制药 公告编号：2025-082 四川汇宇制药股份有限公司 持股 5%以上股东股份被司法冻结及轮候冻结的公告 | 人 | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 黄乾益 | 否 | 否 | 年 | 年 | 四 | 川 | 省 | 泸 | 债 | 务合 | 同 | 5,788,307 | 21.27% | 1.37% | 2025 | 9 | 2028 | | 月 | 日 | 月 | 州 | 市 | 江 | 阳 | 纠纷保全 | 26 | 9 | 24 | | | | | | | | | 日 | 区 | 人 | 民 | 法 | | | | | | | | | | | | | | | 院 | | | | | | | | | | | | | | | | | | | 合计 | 5,788,307 | 21.27% | 1.37% | ...

Core Viewpoint - The announcement reveals that shareholder Huang Qianyi's shares in Huiyu Pharmaceutical have been judicially frozen, impacting both his ownership and the company's total share capital [1] Shareholder Information - Huang Qianyi directly holds 27.2194 million shares, accounting for 6.43% of the company's total share capital [1] - A total of 5.7883 million shares, representing 21.27% of his holdings, have been judicially frozen by the Jiangyang District People's Court in Luzhou, Sichuan [1] - Additionally, 6.0707 million shares have been provisionally frozen, which is 22.30% of his holdings [1] Total Frozen Shares - As of October 9, 2025, the cumulative number of judicially frozen shares held by Huang Qianyi is 27.2194 million, which is 100% of his holdings and 6.43% of the company's total share capital [1] - The cumulative number of provisionally frozen shares is 6.3507 million, accounting for 23.33% of his holdings and 1.50% of the company's total share capital [1]

Core Insights - On October 9, Huayu Pharmaceutical experienced a decline of 0.61% with a trading volume of 74.55 million yuan [1] - The company reported a financing buy-in of 10.62 million yuan and a net financing buy of 2.07 million yuan on the same day [1] - As of October 9, the total balance of margin trading for Huayu Pharmaceutical was 213 million yuan, representing 2.90% of its circulating market value [1] Financing Summary - On October 9, Huayu Pharmaceutical had a financing buy-in of 10.62 million yuan, with a current financing balance of 213 million yuan, which is above the 80th percentile of the past year [1] - The company had no short selling activity on October 9, with a short selling balance of 0.00 yuan, indicating a high level of short selling availability [1] Company Performance - As of June 30, Huayu Pharmaceutical had 16,300 shareholders, a decrease of 11.81% from the previous period, while the average circulating shares per person increased by 25.85% to 21,131 shares [2] - For the first half of 2025, the company reported a revenue of 453 million yuan, a year-on-year decrease of 14.86%, and a net profit attributable to shareholders of -80.72 million yuan, a significant decline of 223.78% [2] - Since its A-share listing, Huayu Pharmaceutical has distributed a total of 474 million yuan in dividends, with 385 million yuan distributed over the past three years [2]

Group 1 - Changyuan Power reported a power generation of 2.742 billion kWh in September, a year-on-year decrease of 41.88% [1] - The cumulative power generation from January to September was 27.332 billion kWh, down 8.24% year-on-year [1] - Huanyu Electronics achieved a consolidated revenue of 5.96 billion yuan in September, a year-on-year increase of 0.1% [1][2] Group 2 - Zhonghuan Environmental announced a change in controlling shareholder, with 27.5% of shares being transferred for a total consideration of 598 million yuan [2] - *ST Songfa's subsidiary signed contracts for the construction of 6 VLCCs, with a total contract value of approximately 600-900 million USD [1][3] - Suzhou Xinchen Technology's subsidiary plans to acquire 55% of Kunyu Lancheng for 74.25 million yuan [3] Group 3 - Guiguan Power reported a cumulative power generation of 31.848 billion kWh for the first three quarters, a year-on-year increase of 14.89% [4] - Jincheng Pharmaceutical's subsidiary received approval for the market launch of a raw material drug [4] - Shandong Steel expects a net profit of approximately 140 million yuan for the first three quarters, an increase of about 21.96 million yuan year-on-year [4][5] Group 4 - Xiangjia Co. reported sales revenue of 96.6186 million yuan from live poultry in September, with a sales price of 12.10 yuan/kg [6] - Aonong Bio's pig sales volume in September increased by 12.2% year-on-year, with a total of 164,400 pigs sold [7] - Mingtai Aluminum's aluminum plate and foil sales reached 1.1747 million tons in the first three quarters [8] Group 5 - Guangzhou Port expects to complete a container throughput of 2.051 million TEUs in September, a year-on-year decrease of 0.8% [11] - Jiangsu Sop plans to conduct a month-long maintenance on several production units starting October 10 [12] - Baike Bio received approval for a clinical trial of a combined vaccine for infants [13] Group 6 - Yutong Bus reported a 25.55% year-on-year increase in bus sales in September, totaling 4,756 units [16] - Shanghai Rural Commercial Bank's vice chairman and president's qualifications were approved [19] - Huayu Pharmaceutical's product received market approval in four countries [20] Group 7 - Longan Automobile reported a 24.92% year-on-year increase in vehicle sales in September, totaling 266,300 units [38] - Chip Origin expects a third-quarter revenue of 1.284 billion yuan, a year-on-year increase of 78.77% [39] - Bomaike signed a contract for an offshore floating production storage and offloading vessel project, with a contract value of approximately 190-240 million USD [40]

Core Viewpoint - The company has received marketing approvals for its injectable paclitaxel (albumin-bound) from multiple European regulatory authorities, indicating a significant advancement in its product offerings and potential market expansion [1] Group 1: Regulatory Approvals - The company's subsidiary, Seacross Pharma (Europe) Ltd., has obtained marketing licenses from the Dutch Medicines Evaluation Board, the Irish Health Products Regulatory Authority, the Finnish Medicines Agency, and the Swedish Medical Products Agency [1] - The approvals pertain to the injectable paclitaxel (albumin-bound) product, which is a key therapeutic option for various cancer treatments [1] Group 2: Indications for Use - The injectable paclitaxel (albumin-bound) is indicated as a monotherapy for adult patients with metastatic breast cancer who have not responded to first-line treatment and are unsuitable for standard anthracycline-based regimens [1] - It is also indicated for use in combination with gemcitabine for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma [1] - Additionally, it can be used in combination with carboplatin for the initial treatment of adult patients with non-small cell lung cancer who are not candidates for potentially curative surgery and/or radiotherapy [1]

Core Viewpoint - Seacross Pharma (Europe) Ltd., a subsidiary of the company, has received marketing approvals for its injectable paclitaxel (albumin-bound) from regulatory authorities in the Netherlands, Ireland, Finland, and Sweden [1] Group 1: Product Approval - The injectable paclitaxel (albumin-bound) is indicated as a monotherapy for adult patients with metastatic breast cancer who have not responded to first-line treatment and for whom standard anthracycline-based therapy is not suitable [1] - The product is also indicated for use in combination with gemcitabine for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma [1] - Additionally, it is indicated for use in combination with carboplatin for the initial treatment of adult patients with non-small cell lung cancer who are not suitable for potentially curative surgery and/or radiotherapy [1]

Core Viewpoint - Seacross Pharma (Europe) Ltd., a subsidiary of Huayu Pharmaceutical, has received marketing authorization for its injectable paclitaxel (albumin-bound) from regulatory authorities in the Netherlands, Ireland, Finland, and Sweden, indicating a significant advancement in the company's product offerings for treating metastatic breast cancer patients [1] Group 1 - The product, injectable paclitaxel (albumin-bound), is primarily indicated as a monotherapy for adult patients with metastatic breast cancer who have not responded to first-line treatment and for whom standard anthracycline-based therapy is not suitable [1]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-081 二、药品的其他相关情况 注射用紫杉醇(白蛋白结合型)主要单药疗法适用于治疗成人转移性乳腺癌 患者（这些患者在一线治疗转移性疾病后病情未见好转，且标准的含蒽环类药物 治疗方案不适用）；与吉西他滨联合使用适用于成人转移性胰腺腺癌患者的首次 治疗；与卡铂联合使用，适用于不适合接受可能具有治愈效果的手术和/或放疗 的成年非小细胞肺癌患者的初始治疗。 公司注射用紫杉醇(白蛋白结合型)研发成功后已进行了多国注册申报，目前 已在丹麦、荷兰、爱尔兰、芬兰、瑞典获得上市许可。截至目前，公司已在包含 英国、意大利、法国、西班牙等 9 个国家提交注册申请。 三、对公司的影响及风险提示 公司研发的注射用紫杉醇(白蛋白结合型)分别获得荷兰、爱尔兰、芬兰、瑞 典的上市许可，有利于公司在国际市场产品管线的丰富，提升市场的品牌形象， 四川汇宇制药股份有限公司 关于自愿披露公司产品获得境外上市许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-080 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、担保情况概述 （一）担保的基本情况 近日，四川汇宇制药股份有限公司（以下简称"公司"、"汇宇制药"）与中 国工商银行股份有限公司新津支行（以下简称"工商银行"、"债权人"）签署《保 证合同》，约定由公司为其全资子公司汇宇海玥向工商银行的借款 1,800.00 万元 提供连带责任保证。保证范围包括主债权本金及其利息、罚息、复利、违约金、 损害赔偿金、实现债权和担保权利的费用。保证期间为汇宇海玥履行债务期限届 满之日起三年。本次担保无反担保。 （二）内部决策程序 公司于 2025 年 9 月 26 日召开了第二届董事会第十九次会议，审议通过了《关 于拟为全资子公司提供担保的议案》。具体内容详见公司于 2025 年 9 月 27 日在 上海证券交易所网站（www.sse.com.cn）披露的《关于拟为全资子公司提供担保 的公告》。本次担保系在上述经董事会批准的额度范围内，无需 ...

Core Viewpoint - Huyou Pharmaceutical's stock has experienced a decline, currently trading at 21.45 yuan, down 3.81%, indicating a state of breaking [1] Group 1: Company Overview - Huyou Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [1] - The company raised a total of 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, exceeding the original fundraising plan by 453 million yuan [2] Group 2: Financial Performance - From 2021 to 2023, the company's operating revenues were 1.824 billion yuan, 1.493 billion yuan, and 927 million yuan, while net profits attributable to shareholders were 446 million yuan, 249 million yuan, and 140 million yuan respectively [3] - In 2024, the company achieved an operating revenue of 1.094 billion yuan, a year-on-year increase of 18.05%, and a net profit of 325 million yuan, a significant increase of 132.78% [3] - For the first half of 2025, the company reported an operating revenue of 453 million yuan, a year-on-year decrease of 14.86%, and a net loss of 80.72 million yuan compared to a profit of 65.21 million yuan in the same period last year [4]